|
The work of Dr. Lippman, a renowned expert in breast cancer research, is noted for its focus on bridging the gap between basic tumor biology and clinical application. Prior to his appointments at the University of Floridan and the University of Michigan, he held a number of positions at Georgetown University Medical School, including Director of the Lombardi Cancer Research Center, Professor and Chairman of the Department of Oncology, Professor of Medicine, and Chief of the Division of Hematology-Oncology. He also served as Head of the Medical Breast Cancer Section of the Medicine Branch of the National Cancer Institute. Dr. Lippman is the recipient of the Clinical Investigator Prize of the American Federation for Clinical Research, the Rosenthal Award of the American Association for Cancer Research, the American Cancer Society Lectureship award given by the American Society for Clinical Oncology, the Astwood Prize of the Endocrine Society, and the Brinker International Prize for Basic Research in Breast Cancer. He is the author of more than 500 publications and one of the standard texts on breast cancer. With sponsorship from Health Care Ventures, he was a cofounder of Oncologix, a diagnostics company that was eventually sold to Aronex; and a cofounder of Peregrine Biotechnology, which was sold to Techniclone. He serves as chair of the Scientific Advisory Board for the Perseus-Soros Fund. In addition to his board position with Raven, Dr. Lippman is a Director of Seattle Genetics. He received a BA from Cornell University and his board position with an MD from Yale University. | 